OTLK · Outlook Therapeutics, Inc.

Summary

Outlook Therapeutics, Inc. closed a best-efforts public offering on March 25, 2026, of 20,000,000 shares of common stock and accompanying warrants to purchase 20,000,000 shares at a combined price of $0.25, raising approximately $5.0 million in gross proceeds and $4.0 million in net proceeds. This financing provides capital but involves substantial dilution from new shares and exercisable warrants.

Key takeaways

• Commenced offering March 23, 2026; closed March 25, 2026
• Issued 20,000,000 common shares (par $0.01) and warrants for 20,000,000 shares
• Combined offering price $0.25 per share and warrant
• Gross proceeds $5.0 million; net proceeds $4.0 million after fees and expenses
• H.C. Wainwright & Co., LLC as placement agent; received warrants for 1,400,000 shares at $0.3125 exercise price
• Warrants exercisable immediately at $0.25, expire in 5 years, with 4.99%/9.99% ownership cap